Etoposide and temozolomide in combination for the treatment of progressive small-cell lung cancer central nervous system metastases: two cases.
Rimas V Lukas, Janani Vigneswaran, Ravi Salgia
Index: Tumori 99(2) , e73-6, (2013)
Full Text: HTML
Abstract
Progression of central nervous system (CNS) metastases from small cell lung cancer (SCLC) after radiation therapy is associated with a poor prognosis.We present two cases of patients with progressive CNS metastases from SCLC treated with oral temozolomide and etoposide. Sustained clinical responses and radiographic stability were demonstrated. The palliative chemotherapy regimen was well tolerated.A regimen of oral temozolomide and etoposide for progressive CNS metastases from SCLC is well tolerated and may be associated with sustained stability of disease.
Related Compounds
Related Articles:
TAp73 promotes cell survival upon genotoxic stress by inhibiting p53 activity.
2014-09-30
[Oncotarget 5(18) , 8107-22, (2014)]
DNA damage-specific deubiquitination regulates Rad18 functions to suppress mutagenesis.
2014-07-21
[J. Cell Biol. 206(2) , 183-97, (2014)]
SK053 triggers tumor cells apoptosis by oxidative stress-mediated endoplasmic reticulum stress.
2015-02-15
[Biochem. Pharmacol. 93(4) , 418-27, (2015)]
2014-12-01
[Mol. Cell Biochem. 397(1-2) , 33-43, (2014)]
High-throughput screening identifies inhibitors of DUX4-induced myoblast toxicity.
2014-01-01
[Skelet. Muscle 4 , 4, (2014)]